CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-04 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −106 | $319.03 | $34K | 36,500 |
| 2026-03-04 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −102 | $320.01 | $33K | 36,398 |
| 2026-03-04 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −215 | $320.81 | $69K | 36,183 |
| 2026-03-04 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −289 | $321.82 | $93K | 35,894 |
| 2026-03-04 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −350 | $323.01 | $113K | 35,544 |
| 2026-03-04 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −767 | $323.84 | $248K | 34,777 |
| 2026-03-04 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −272 | $324.88 | $88K | 34,505 |
| 2026-03-04 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −208 | $325.67 | $68K | 34,297 |
| 2026-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −29 | $319.03 | $9K | 21,831 |
| 2026-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −28 | $320.01 | $9K | 21,803 |
| 2026-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −59 | $320.81 | $19K | 21,744 |
| 2026-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −79 | $321.82 | $25K | 21,665 |
| 2026-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −96 | $323.01 | $31K | 21,569 |
| 2026-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −210 | $323.84 | $68K | 21,359 |
| 2026-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −75 | $324.88 | $24K | 21,284 |
| 2026-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −57 | $325.67 | $19K | 21,227 |
| 2026-03-03 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −355 | $316.74 | $112K | 24,826 |
| 2026-03-03 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −317 | $319.06 | $101K | 24,509 |
| 2026-03-03 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −640 | $320.48 | $205K | 23,869 |
| 2026-03-03 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −463 | $321.50 | $149K | 23,406 |
Page 5 of 41 · 816 trades